Table 1 Main baseline characteristics of the study population
From: Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
N (%) | Serum kyn/trp ratio (µg/ml) | Serum quinolic acid concentration (ng/ml) | |
|---|---|---|---|
Age | |||
< 65 | 11 (42.3) | 0.06 ± 0.03 | 74.47 ± 45.93 |
65+ | 15 (57.7) | 0.08 ± 0.05 | 102.55 ± 72.99 |
Sex | |||
Male | 20 (76.9) | 0.08 ± 0.04 | 99.21 ± 69.37 |
Female | 6 (23.1) | 0.05 ± 0.02 | 62.22 ± 24.24 |
Histology | |||
Adenocarcinoma | 6 (23.1) | 0.09 ± 0.04 | 127.85 ± 59.78 |
Squamous-cell carcinoma | 19 (73.1) | 0.07 ± 0.04 | 79.69 ± 63.25 |
Undifferentiated tumor | 1 (3.8) | 0.04 | 76.2 |
ECOG PS | |||
0–1 | 25 (96.2) | 0.07 ± 0.03 | 88.26 ± 63.54 |
> 1 | 1 (3.8) | 0.18 | 151 |
Cerebral metastasis | |||
Yes | 3 (11.5) | 0.05 ± 0.04 | 91.54 ± 64.77 |
No | 23 (88.5) | 0.08 ± 0.04 | 84.03 ± 64.14 |
Pleural effusion | |||
Yes | 6 (23.1) | 0.07 ± 0.04 | 79.24 ± 45.54 |
No | 20 (76.9) | 0.09 ± 0.05 | 110.39 ± 99.95 |
Early progressor | |||
Yes | 14 (53.8) | 0.09 ± 0.05 | 121.15 ± 72.34 |
No | 12 (46.2) | 0.05 ± 0.01 | 55.12 ± 20.18 |